• Home
  • PATH-30. CLINICAL OUTCOMES AND PREDICTIVE BIOMARKERS FOR IDH-WILDTYPE GLIOBLASTOMAS DEVELOPING HYPERMUTATION FOLLOWING TEMOZOLOMIDE TREATMENT.

PATH-30. CLINICAL OUTCOMES AND PREDICTIVE BIOMARKERS FOR IDH-WILDTYPE GLIOBLASTOMAS DEVELOPING HYPERMUTATION FOLLOWING TEMOZOLOMIDE TREATMENT.

Author List
Jacob Young, Calixto-Hope Lucas, Nadeem Al-Adli, Rohit Gupta, Ramin Morshed, Jasper Wu, Ajay Ravindranathan, Anny Shai, Nancy Ann Oberheim-Bush, Jennie Taylor, John de Groot, Javier Villanueva-Meyer, Melike Pekmezci, Arie Perry, Andy Bollen, Philip Theodosopoulos, Manish Aghi, Edward Chang, Shawn Hervey-Jumper, David Raleigh, Aaron Diaz, Joseph Costello, Jennifer Clarke, Nicholas Butowski, Joanna Phillips, Susan Chang, Mitchel Berger, David Solomon
Publication
Neuro-oncology
Publication ID (Profile URL)
https://researcherprofiles.org/profile/564361723
Publication Year
2024
Publication Title
Jacob Young, Calixto-Hope Lucas, Nadeem Al-Adli, Rohit Gupta, Ramin Morshed, Jasper Wu, Ajay Ravindranathan, Anny Shai, Nancy Ann Oberheim-Bush, Jennie Taylor, John de Groot, Javier Villanueva-Meyer, Melike Pekmezci, Arie Perry, Andy Bollen, Philip Theodosopoulos, Manish Aghi, Edward Chang, Shawn Hervey-Jumper, David Raleigh, Aaron Diaz, Joseph Costello, Jennifer Clarke, Nicholas Butowski, Joanna Phillips, Susan Chang, Mitchel Berger, David Solomon. PATH-30. CLINICAL OUTCOMES AND PREDICTIVE BIOMARKERS FOR IDH-WILDTYPE GLIOBLASTOMAS DEVELOPING HYPERMUTATION FOLLOWING TEMOZOLOMIDE TREATMENT. Neuro-Oncology. 2024 Nov 11; 26(Supplement_8):viii185-viii185.